C07H 19/11
Containing cyclic phosphate
Official title: containing cyclic phosphate
C07H19/11 (Containing cyclic phosphate) appears on 75 US grants and 108 published applications in this corpus.
Search patents in C07H- Granted patents
- 75
- Published applications
- 108
- Assignees
- 45
- Inventors
- 184
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 5 |
| 2013 | 3 | 3 |
| 2014 | 4 | 14 |
| 2015 | 5 | 9 |
| 2016 | 8 | 11 |
| 2017 | 13 | 11 |
| 2018 | 9 | 9 |
| 2019 | 8 | 11 |
| 2020 | 6 | 10 |
| 2021 | 7 | 5 |
| 2022 | 2 | 6 |
| 2023 | 5 | 5 |
| 2024 | 2 | 3 |
| 2025 | 1 | 1 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Asymmetric auxiliary group24 Mar 2026US 12,583,883 B2Wave Life Sciences Ltd.
- N4-hydroxycytidine and derivatives and anti-viral uses related thereto17 Feb 2026US 12,551,497 B2Emory University
- Chiral phosphoramidite auxiliaries and methods of their use8 Apr 2025US 12,269,839 B2Sirius Therapeutics, Inc.
- Cyclic deoxyribonucleotide compounds8 Oct 2024US 12,110,311 B2Nucorion Pharmaceuticals, Inc.
- Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds3 Sep 2024US 12,077,558 B2Bristol-Myers Squibb Company
- N4-hydroxycytidine and derivatives and anti-viral uses related thereto25 Jun 2026US 2026/0174789 A1Emory University
- 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto7 May 2026US 2026/0124226 A1Emory University
- Cyclic phosphoramidate compounds12 Jun 2025US 2025/0188111 A1
- Cyclic deoxyribonucleotide compounds26 Dec 2024US 2024/0425542 A1Nucorion Pharmaceuticals, Inc.
- Unnatural configuration nucleotide prodrug compounds5 Sep 2024US 2024/0294565 A1Ligand Pharmaceuticals Incorporated
Most cited
By later US patents
- 2′-chloroacetylenyl substituted nucleoside derivatives67US 8,575,119 B2Enanta Pharmaceuticals, Inc. · 2013
- Cyclic nucleotide analogs61US 8,772,474 B2Alios BioPharma, Inc. · 2014
- Azido nucleosides and nucleotide analogs59US 8,877,731 B2Alios BioPharma, Inc. · 2014
- 5′ phosphate mimics58US 8,927,513 B2Alnylam Pharmaceuticals, Inc. · 2015
- HCV polymerase inhibitors53US 9,828,408 B2Medivir AB · 2017